Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
23 July, 2018 19:13 IST
Zydus receives final approval from USFDA for Zolmitriptan tablets
Source: IRIS | 12 Jul, 2018, 10.37AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the USFDA to market Zolmitriptan Tablets, 2.5 mg and 5 mg. It is used to treat migraines. It helps to relieve headache, pain, and other migraine symptoms (including nausea, vomiting and sensitivity to light/sound). It will be manufactured at the group's manufacturing facility at Moraiya, Ahmedabad.

In line with this, the group now has 203 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 2.55, or 0.69%, to trade at Rs 368.95. The total volume of shares traded was 37,256 at the BSE (10.24 a.m., Thursday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
ACC quarterly earnings rise 0.92% - 23-Jul-2018 17:10
Maruti Suzuki achieves production milestone in India - 23-Jul-2018 16:35
Welspun Corp quarterly earnings decline 14% - 23-Jul-2018 15:54
Hindustan Zinc quarterly earnings up 1.5% - 23-Jul-2018 15:33
Hindustan Oil Exploration quarterly net soars 7.95 times - 23-Jul-2018 15:25
Vijaya Bank quarterly earnings plunges 43% - 23-Jul-2018 15:11
Sterlite Technologies arm completes acquisition of Metallurgica Bresciana - 23-Jul-2018 12:33
Suven participates at Alzheimer's Association International Conference - 23-Jul-2018 12:14
HDFC Bank quarterly net climbs 18% to Rs 46.01 bn - 23-Jul-2018 10:48
Thomas Cook inks long term pact with Seoul Tourism - 23-Jul-2018 10:33
CG Power & Industrial Solutions sells biz in Hungary - 23-Jul-2018 09:54
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer